keyword
MENU ▼
Read by QxMD icon Read
search

Maintenance chemotherapy in metastatic triple negative breast cancer patients

keyword
https://www.readbyqxmd.com/read/27412268/weekly-paclitaxel-capecitabine-and-bevacizumab-with-maintenance-capecitabine-and-bevacizumab-as-first-line-therapy-for-triple-negative-metastatic-or-locally-advanced-breast-cancer-results-from-the-gineco-a-taxel-phase-2-study
#1
Jean-Marc Ferrero, Anne-Claire Hardy-Bessard, Olivier Capitain, Alain Lortholary, Bruno Salles, Philippe Follana, Robert Herve, Mathilde Deblock, Jérôme Dauba, Mustapha Atlassi, Rémy Largillier
BACKGROUND: The current study was performed to determine the efficacy and safety of first-line combination therapy with bevacizumab, paclitaxel, and capecitabine for triple-negative, locally advanced/metastatic breast cancer (LA/MBC). METHODS: Patients with measurable triple-negative LA/MBC who had received no prior chemotherapy for their disease received 4-weekly cycles of paclitaxel (80 mg/m(2) on days 1, 8, and 15 for up to 6 cycles) combined with capecitabine (800 mg/m(2) twice daily on days 1-5, 8-12, and 15-19) and bevacizumab (10 mg/kg on days 1 and 14) repeated every 4 weeks until disease progression or unacceptable toxicity occurred...
October 15, 2016: Cancer
https://www.readbyqxmd.com/read/26266766/prospective-study-of-cyclophosphamide-thiotepa-carboplatin-combined-with-adoptive-dc-cik-followed-by-metronomic-cyclophosphamide-therapy-as-salvage-treatment-for-triple-negative-metastatic-breast-cancers-patients-aged-45
#2
X Wang, J Ren, J Zhang, Y Yan, N Jiang, J Yu, L Di, G Song, L Che, J Jia, X Zhou, H Yang, H K Lyerly
BACKGROUND: The recent immunotherapy treatment on triple-negative breast cancer (TNBC) leads to the breakthrough assignation. In this study, we have tried the new combinations of specific chemo with DC-CIKs immunotherapy to treat those patients. PATIENTS AND METHODS: Twenty-three metastatic anthracyclines and taxanes pretreated TNBC younger (mean 41.5 years) patients were initially mobilized with cyclophosphamide (3 g/m(2)) for the preparation of CD34(+) peripheral blood mononuclear cells as the resources for generating DC/CIKs and marrow function supports...
January 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/25963688/-progress-in-second-line-therapies-for-metastatic-breast-cancer
#3
Takashi Shigekawa, Akihiko Osaki, Toshiaki Saeki
It may be difficult to achieve complete cure for most metastatic breast cancer patients;thus, prolongation of overall survival and maintenance of the quality of life are often the main focus of treatment. In the treatment of metastatic breast cancer patients, it is important to choose the most appropriate therapeutic strategy based on substantial evidence that considers the biology of the tumor, including estrogen receptor(ER), progesterone receptor(PgR), and human epidermal growth factor receptor 2(HER2)status;the site and extent of the metastatic focus;the time to recurrence;prior treatment regimens;age; menopausal status;performance status;and the preference of the patient...
April 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25400420/capecitabine-maintenance-therapy-for-xt-chemotherapy-sensitive-patients-with-metastatic-triple-negative-breast-cancer
#4
Xu Liang, Lijun Di, Guohong Song, Ying Yan, Chaoying Wang, Hanfang Jiang, Huiping Li
OBJECTIVE: To investigate the efficacy and safety of capecitabine maintenance therapy (MT) after initial capecitabine plus docetaxel (XT) chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC). METHODS: Fifty-five mTNBC patients treated with XT chemotherapy between May 2007 and June 2013 were retrospectively analyzed. When initial disease control was achieved by the combination chemotherapy, capecitabine was continued for 32 patients (MT), while 23 patients remained without any treatment (non-MT)...
October 2014: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/23718667/-antiangiogenic-biotherapy-and-chemotherapy-in-breast-cancer-review-of-literature-and-case-report
#5
M Sochor, P Chlebus
Breast cancer incidence is 120/100,000 women and thus, it is the most frequent malignant disease in women. Despite the ever-increasing incidence, mortality has stayed stable; this is due to screening with detection of early breast cancers, adjuvant treatment and advances in targeted therapy. Currently, we perceive breast cancer as a phenotypically different subunits, influenced by genetic and epigenetic changes. All 5 basic subgroups (luminal A, B, basal-like, HER-2 positive and claudin-low) vary significantly in their prognosis and therapeutic options...
2013: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"